SCHEMBL1133971

SCHEMBL1133971

CC(=O)Nc1ccc(OC(=O)C(CS)NC(C)=O)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 8/20 0.57
MEN1 O00255 4/20 0.57
SMN1; SMN2 Q16637 3/20 0.50
HSD17B10 Q99714 3/20 0.50
NPSR1 Q6W5P4 1/20 0.50
LMNA P02545 1/20 0.49
CYP1A2 P05177 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
OPRK1 P41145 1/20 0.48
ALDH1A1 P00352 5/20 0.47
MAPT P10636 3/20 0.47
HPGD P15428 3/20 0.45
KDM4E B2RXH2 2/20 0.44
TSHR P16473 1/20 0.44
GLA P06280 1/20 0.44
THRB P10828 1/20 0.44
ALOX15 P16050 1/20 0.44
NFKB1 P19838 1/20 0.44
PTGS2 P35354 1/20 0.44
THPO P40225 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13143432 1.00 KMT2A (0.57) KMT2AMEN1SMN1; SMN2HSD17B10NPSR1
SCHEMBL965165 1.00 KMT2A (0.57) KMT2AMEN1SMN1; SMN2HSD17B10NPSR1
SCHEMBL11080172 0.89 KMT2A (0.54) KMT2AMEN1SMN1; SMN2HSD17B10NPSR1
SCHEMBL12229256 0.85 LMNA (0.47) KMT2AMEN1SMN1; SMN2LMNAALDH1A1
SCHEMBL1133950 0.84 KMT2A (0.55) KMT2AMEN1SMN1; SMN2HSD17B10NPSR1
SCHEMBL1133962 0.84 KMT2A (0.55) KMT2AMEN1SMN1; SMN2HSD17B10NPSR1
SCHEMBL13143428 0.82 KMT2A (0.53) KMT2AMEN1SMN1; SMN2HSD17B10NPSR1
SCHEMBL13143430 0.82 KMT2A (0.53) KMT2AMEN1SMN1; SMN2HSD17B10NPSR1
SCHEMBL13143429 0.82 KMT2A (0.53) KMT2AMEN1SMN1; SMN2HSD17B10NPSR1
Sumacetamol SCHEMBL5185790 0.81 GAA (0.55) KMT2AMEN1SMN1; SMN2HSD17B10NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9951001-B2 Hepatoprotectant acetaminophen mutual prodrugs ACORDA THERAPEUTICS, INC. (US) 2018-04-24 US disclosed
US-20160326107-A1 HEPATOPROTECTANT ACETAMINOPHEN MUTUAL PRODRUGS NEUROGESX, INC. 2016-11-10 US disclosed
US-20160326107-A1 HEPATOPROTECTANT ACETAMINOPHEN MUTUAL PRODRUGS NEUROGESX, INC. 2016-11-10 US disclosed
US-8575217-B2 Anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders GENMEDICA THERAPEUTICS SL (ES) 2013-11-05 US disclosed
US-8575217-B2 Anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders GENMEDICA THERAPEUTICS SL (ES) 2013-11-05 US disclosed
US-20130281520-A1 Anti-Inflammatory And Antioxidant Conjugates Useful For Treating Metabolic Disorders GENMEDICA THERAPEUTICS SL (ES) 2013-10-24 US disclosed
US-20110263545-A1 HEPATOPROTECTANT ACETAMINOPHEN MUTUAL PRODRUGS ACORDA THERAPEUTICS, INC. 2011-10-27 US disclosed
US-20110263545-A1 HEPATOPROTECTANT ACETAMINOPHEN MUTUAL PRODRUGS ACORDA THERAPEUTICS, INC. 2011-10-27 US disclosed
EP-2285419-A1 HEPATOPROTECTANT ACETAMINOPHEN MUTUAL PRODRUGS Neurogesx, Inc. (US) 2011-02-23 EP disclosed
US-20100234452-A1 Anti-Inflammatory and Antioxidant Conjugates Useful for Treating Metabolic Disorders GENMEDICA THERAPEUTICS SL (ES) 2010-09-16 US disclosed
US-20100234452-A1 Anti-Inflammatory and Antioxidant Conjugates Useful for Treating Metabolic Disorders GENMEDICA THERAPEUTICS SL (ES) 2010-09-16 US disclosed
WO-2009143299-A1 HEPATOPROTECTANT ACETAMINOPHEN MUTUAL PRODRUGS NEUROGESX, INC. (US) 2009-11-26 WO disclosed
WO-2009143299-A1 HEPATOPROTECTANT ACETAMINOPHEN MUTUAL PRODRUGS NEUROGESX, INC. (US) 2009-11-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160326107-A1 HEPATOPROTECTANT ACETAMINOPHEN MUTUAL PRODRUGS PTGS1, HPGD, PYGL KMT2A 4597/4885MEN1 4430/4885SMN1; SMN2 1818/4885
US-20130281520-A1 Anti-Inflammatory And Antioxidant Conjugates Useful For Treating Metabolic Disorders HSD17B14, SORD, GPX4 KMT2A 3962/4885MEN1 2842/4885SMN1; SMN2 2940/4885
US-20100234452-A1 Anti-Inflammatory and Antioxidant Conjugates Useful for Treating Metabolic Disorders HSD17B14, SORD, GPX4 KMT2A 3962/4885MEN1 2842/4885SMN1; SMN2 2940/4885
US-20110263545-A1 HEPATOPROTECTANT ACETAMINOPHEN MUTUAL PRODRUGS PTGS1, HPGD, PYGL KMT2A 4597/4885MEN1 4430/4885SMN1; SMN2 1818/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.